Key Takeaways Energy Fuels' Q1 2025 revenues dropped 33.5% to $16.9M after holding back uranium sales due to price weakness. HMS segment brought in $15.5M in Q1 from rutile, ilmenite and zircon sales, mainly from the Kwale Project. Energy Fuels is advancing HMS projects in Madagascar, Brazil and Australia to diversify and cut supply costs.Energy Fuels (UUUU) reported a 33.5% decline in revenues in the first quarter of 2025 to $16.9 million owing to its decision to withhold uranium sales amid declining pri ...

For the better part of the past year, Occidental Petroleum Corp. OXY has looked like the blemish on Warren Buffett's otherwise bulletproof track record. With shares down 27% over the past 12 months and well below Buffett's average cost basis of $54.20, the Oracle of Omaha's massive $12 billion stake in the oil giant had critics wondering if this was one value bet that misfired.Chart created using Benzinga ProBut that skepticism may be premature. OXY has quietly rebounded nearly 9% over the past month and is ...

Key Takeaways SNOW shares are up 37.3% YTD, trading just 1.28% below their 52-week high of $214.83. Revenues rose 25.7% to $1.04B in Q1, with 451 new customers and EPS beating estimates at 24 cents. SNOW launched Gen 2 Warehouses and AI tools to boost adoption, but valuation remains a concern.Snowflake (SNOW) shares closed at $212.08 on Wednesday, very close to the 52-week high of $214.83, hit on June 4, 2025. SNOW shares have jumped 37.3% year to date (YTD), outperforming the Zacks Internet - Software in ...

we discuss ideas like this as they happen in more detail. All active investors are welcome to join on a free trial and ask any question in our chat room full of sophisticated traders and investors.As global tensions rise, investors traditionally keep a closer eye on their portfolios and start looking for safer investment bets. The fear of a big war could decrease liquidity and increase volatility in many industryDenislav leads the investing group Trade With Beta , features of the service include: frequent p ...

Key Takeaways SNN partners with Standard Health to open the UK's first Orthopaedic ASC, starting in Poole, Dorset. SNN's advanced technologies will power minimally invasive procedures across joint and limb surgeries. Smith Nephew may benefit as Standard Health targets 20 ASC sites across the United Kingdom by 2030.Smith + Nephew (SNN) recently announced a strategic partnership with Standard Health to establish the United Kingdom’s first dedicated Orthopaedic Ambulatory Surgery Centre (ASC), located in Poo ...

Investors with an interest in Financial - Investment Bank stocks have likely encountered both UP Fintech Holding Limited (TIGR) and Tradeweb Markets (TW) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Illumina (ILMN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts ...

TerraPower, the nuclear startup founded and backed by Bill Gates, announced a new $650 million funding round this week. The investment will help the company build its first commercial power plant.Like other nuclear startups, TerraPower has been riding a wave of interest from hyperscalers, data center developers, and, now, chip designers. Nvidia’s venture arm, NVentures, participated in the round, marking its first energy investment. Bill Gates and HD Hyundai, both already on the cap table, also invested.Te ...

股价表现 - 公司股价在过去一个月上涨约6%，表现优于标普500指数[1] 盈利预测 - 过去一个月盈利预测呈下降趋势，共识预期下调6.38%[2] - 整体盈利预测持续下行，Zacks评级为4级（卖出），预计未来几个月回报低于平均水平[4] VGM评分 - 公司增长评分为B，动量评分为F，价值评分为C[3] - 综合VGM评分为C，显示中等投资吸引力[3] 行业对比 - 同属医疗产品行业的Phibro Animal Health过去一个月股价上涨4.1%[5] - Phibro上季度营收3.478亿美元，同比增长32.1%，每股收益0.63美元（去年同期0.31美元）[5] - Phibro当前季度预期每股收益0.52美元，同比增长26.8%，Zacks评级为1级（强力买入），VGM评分为A[6]

股价表现与市场对比 - 公司股价在过去一个月仅上涨0.1%，表现逊于同期标普500指数[1] 盈利预测调整 - 过去一个月市场对公司盈利预期呈下调趋势，共识预期累计下调12.38%[2] 投资策略评分 - 公司成长性评分为C级，动量评分表现较差为F级，但价值评分达到A级（位列前20%）[3] - 综合VGM评分为C级，反映其多策略平衡表现[3] 市场展望 - 盈利预期持续下调且幅度显著，当前Zacks评级为3级（持有），预计未来数月回报率与市场持平[4]